Spyre Therapeutics Inc. annual gross profit for fiscal 2025 was -$172 million, compared with $1 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Gross Profit (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | — | ($172M) | $1M | $0M | $2M | $19M | ($2M) | ($1M) | $4M | $5M | $5M | $6M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Gross Profit (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | — | — | $45M | ($45M) | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More SYRE metrics: Revenue · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All SYRE financial statements → Interactive SYRE charts →
About TickerBase · Data methodology & sources · Privacy · Terms